睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 66 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 66

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心广州医科大学附属肿瘤医院Affiliated Cancer Hospital of Guangzhou Medical University广州医院页面
  2. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  3. 研究中心桂林医学院附属医院Affiliated Hospital of Guilin Medical University桂林医院页面
  4. 研究中心河北大学附属医院Affiliated Hospital of Hebei University石家庄医院页面
  5. 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
  6. 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
  7. 研究中心安阳市肿瘤医院Anyang Tumor Hospital安阳医院页面
  8. 研究中心滨州医学院附属医院Binzhou Medical University Hospital烟台医院页面
  9. 研究中心沧州市中心医院Cangzhou Central Hospital天津医院页面
  10. 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
  11. 研究中心中山大学附属第五医院Fifth Affiliated Hospital of Sun Yat-sen University珠海医院页面
  12. 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
  13. 研究中心广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面
  14. 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
  15. 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
  16. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  17. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  18. 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
  19. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  20. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  21. 研究中心河南医药大学第一附属医院First Affiliated Hospital of Xinxiang Medical University新乡医院页面
  22. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  23. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  24. 研究中心兰州大学第一医院First Hospital of Lanzhou University兰州医院页面
  25. 研究中心山西医科大学第一医院First Hospital of Shanxi Medical University太原医院页面
  26. 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
  27. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  28. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  29. 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
  30. 研究中心宁夏医科大学总医院General Hospital of Ningxia Medical University银川医院页面
  31. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  32. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  33. 研究中心河南省人民医院Henan Provincial People's Hospital郑州医院页面
  34. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  35. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  36. 研究中心江门市中心医院Jiangmen Central Hospital江门医院页面
  37. 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
  38. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  39. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  40. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  41. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  42. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  43. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  44. 研究中心重庆医科大学附属第二医院Second Affiliated Hospital of Chongqing Medical University重庆医院页面
  45. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
  46. 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
  47. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  48. 研究中心深圳市人民医院Shenzhen People's Hospital深圳医院页面
  49. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  50. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  51. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  52. 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
  53. 研究中心天津市胸科医院Tianjin Chest Hospital天津医院页面
  54. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  55. 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
  56. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  57. 研究中心四川大学华西医院West China Hospital成都医院页面
  58. 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
  59. 研究中心襄阳市中心医院Xiangyang Central Hospital襄阳医院页面
  60. 研究中心陆军军医大学第二附属医院(新桥医院)Xinqiao Hospital, Army Medical University重庆医院页面
  61. 研究中心徐州市中心医院Xuzhou Central Hospital徐州医院页面
  62. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
  63. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  64. 研究中心东南大学附属中大医院Zhongda Hospital, Southeast University南京医院页面
  65. 研究中心武汉大学中南医院Zhongnan Hospital of Wuhan University武汉医院页面
  66. 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07416474,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histopathologically or cytologically confirmed locally advanced or metastatic NSCLC not eligible for curative treatment.

    入选标准第 6 条

  3. Female participants must be postmenopausal, surgically sterilized, or of childbearing potential with a negative blood pregnancy test within 7 days before the first dose. Female participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate oocytes or breastfeed during this period. Male participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate sperm during this period.

    入选标准第 9 条

    Prior systemic anti-tumor treatment other than chemotherapy and PD-1/PD-L1 antibodies.

    排除标准第 7 条

    Toxic reactions from prior anti-tumor treatment have not recovered to grade 0-1 as defined by CTCAE version 6.0.

    排除标准第 13 条

    Other malignant tumors within 5 years before the start of study drug administration, except for malignant tumors that are expected to be cured after treatment.

    排除标准第 25 条

    For participants who have used PD-1/L1 inhibitors, prior occurrence of grade 3 or above irAE related to immunotherapy, irAE leading to permanent discontinuation of treatment, grade 2 immune-related cardiotoxicity, or irAE of any grade involving the nervous system or eyes; prior occurrence of adverse events requiring treatment with immunosuppressive drugs other than corticosteroids, or recurrence of adverse events during previous immunotherapy requiring systemic use of corticosteroids again.

    排除标准第 29 条

  4. ECOG PS score 0 or 1.

    入选标准第 5 条

  5. At least one measurable lesion outside of the brain according to the RECIST v1.1 criteria.

    入选标准第 10 条

  6. Histopathologically or cytologically confirmed non-squamous non-small cell lung cancer.

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07416474,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily participate in the study and signed the Informed Consent Form (ICF).
  2. Be willing to and able to participate in the trial and comply with the follow up procedures;
  3. Male or female, aged 18-75 years.
  4. Expected survival ≥ 3 months.
  5. ECOG PS score 0 or 1.
  6. Histopathologically or cytologically confirmed locally advanced or metastatic NSCLC not eligible for curative treatment.
  7. No prior systemic anti-tumor treatment for advanced or metastatic squamous NSCLC.
  8. Sufficient cardiac, bone marrow, hepatic, renal, and coagulation function.
  9. Female participants must be postmenopausal, surgically sterilized, or of childbearing potential with a negative blood pregnancy test within 7 days before the first dose. Female participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate oocytes or breastfeed during this period. Male participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate sperm during this period.
  10. At least one measurable lesion outside of the brain according to the RECIST v1.1 criteria.
  11. A PD-L1 expression test report that meets the requirements must be provided before enrollment.

排除标准:Exclusion Criteria:

  1. Histopathologically or cytologically confirmed non-squamous non-small cell lung cancer.
  2. Squamous NSCLC with known EGFR sensitive mutations and ALK fusions; squamous NSCLC with known driver gene for which first-line approved treatment options exist.
  3. Presence of active brain metastases.
  4. Imaging at screening shows obvious tumor necrosis and cavitation, and the investigator judges that participation in the study will cause bleeding risk.
  5. Chest radiotherapy > 30Gy within 6 months before randomization; palliative local treatment for non-target lesions within 2 weeks before randomization; non-specific immunomodulatory treatment within 2 weeks before randomization; Chinese herbal medicine or proprietary Chinese medicine treatment with anti-tumor indications within 1 week before randomization.
  6. History of immunotherapy. Note: For adjuvant/neoadjuvant phases or curative radiotherapy/chemoradiotherapy, PD-L1/PD-1 antibody therapy should be administered only if recurrence or metastasis occurs more than 12 months after the completion of the last medication.
  7. Prior systemic anti-tumor treatment other than chemotherapy and PD-1/PD-L1 antibodies.
  8. Systemic treatment with corticosteroids or other immunosuppressive drugs within 2 weeks before randomization.
  9. Use of any live or attenuated live vaccines within 4 weeks before randomization, or planned during the study.
  10. Participation in other clinical trials within 4 weeks before randomization.
  11. Major surgery, interventional therapy, or severe trauma within 4 weeks before randomization, or planned major surgery during the study; core needle biopsy or other minor surgery within 7 days before randomization.
  12. Participants with history of severe coagulation dysfunction or current intake of anticoagulant drugs.
  13. Toxic reactions from prior anti-tumor treatment have not recovered to grade 0-1 as defined by CTCAE version 6.0.
  14. Severe acute or chronic infections.
  15. Active gastrointestinal bleeding, hemoptysis, peptic ulcer, or hemorrhagic events requiring intervention within 4 weeks before randomization; or presence of severe esophagogastric varices or epistaxis.
  16. Severe arterial/venous thrombotic events or cerebrovascular accidents within 6 months before randomization.
  17. Active or clinically significant heart disease.
  18. Past or current interstitial lung disease, drug-related pneumonia, radiation pneumonitis, severe impairment of lung function, or clinical manifestations or high-risk factors suspected of interstitial lung disease.
  19. History of gastrointestinal perforation and/or fistula, history of gastrointestinal obstruction within 6 months before randomization.
  20. Presence of systemically diseases that are not stably controlled as judged by the investigator.
  21. Active or history of autoimmune diseases with potential for recurrence.
  22. Past history of other acquired or congenital immunodeficiency diseases or organ transplantation.
  23. Known hypersensitivity or delayed-type hypersensitivity to certain components of the study drug or similar drugs.
  24. Presence of symptomatic or intervention-requiring third-space effusions.
  25. Other malignant tumors within 5 years before the start of study drug administration, except for malignant tumors that are expected to be cured after treatment.
  26. Poor compliance and expected inability to cooperate with the completion of trial procedures.
  27. Past or current history of any other diseases, abnormal physical examination findings, or abnormal laboratory examination findings that, in the investigator's judgment, reasonably suggest that the participant has a disease or condition unsuitable for the use of the study drug.
  28. Local or systemic diseases not caused by malignant tumors, or diseases or symptoms secondary to tumors.
  29. For participants who have used PD-1/L1 inhibitors, prior occurrence of grade 3 or above irAE related to immunotherapy, irAE leading to permanent discontinuation of treatment, grade 2 immune-related cardiotoxicity, or irAE of any grade involving the nervous system or eyes; prior occurrence of adverse events requiring treatment with immunosuppressive drugs other than corticosteroids, or recurrence of adverse events during previous immunotherapy requiring systemic use of corticosteroids again.

引自 ClinicalTrials.gov, NCT07416474, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07416474,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07416474